nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Prednisolone—ankylosing spondylitis	0.186	0.221	CbGbCtD
Nevirapine—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.113	0.134	CbGbCtD
Nevirapine—CYP2A6—Dexamethasone—ankylosing spondylitis	0.11	0.13	CbGbCtD
Nevirapine—CYP2B6—Dexamethasone—ankylosing spondylitis	0.0713	0.0848	CbGbCtD
Nevirapine—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0579	0.0689	CbGbCtD
Nevirapine—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0562	0.0668	CbGbCtD
Nevirapine—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0439	0.0522	CbGbCtD
Nevirapine—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0377	0.0448	CbGbCtD
Nevirapine—CYP3A4—Betamethasone—ankylosing spondylitis	0.0377	0.0448	CbGbCtD
Nevirapine—CYP3A4—Prednisolone—ankylosing spondylitis	0.0372	0.0442	CbGbCtD
Nevirapine—CYP3A4—Prednisone—ankylosing spondylitis	0.0351	0.0417	CbGbCtD
Nevirapine—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0345	0.041	CbGbCtD
Nevirapine—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0219	0.026	CbGbCtD
Nevirapine—Skin exfoliation—Betamethasone—ankylosing spondylitis	0.00105	0.00661	CcSEcCtD
Nevirapine—Skin exfoliation—Dexamethasone—ankylosing spondylitis	0.00105	0.00661	CcSEcCtD
Nevirapine—Hepatotoxicity—Methotrexate—ankylosing spondylitis	0.00104	0.00653	CcSEcCtD
Nevirapine—Necrosis—Methotrexate—ankylosing spondylitis	0.00102	0.00642	CcSEcCtD
Nevirapine—Ulcer—Prednisone—ankylosing spondylitis	0.00101	0.00638	CcSEcCtD
Nevirapine—Hypercholesterolaemia—Prednisone—ankylosing spondylitis	0.00101	0.00638	CcSEcCtD
Nevirapine—Dermatitis bullous—Prednisolone—ankylosing spondylitis	0.001	0.0063	CcSEcCtD
Nevirapine—Dermatitis bullous—Triamcinolone—ankylosing spondylitis	0.000919	0.0058	CcSEcCtD
Nevirapine—Skin exfoliation—Prednisone—ankylosing spondylitis	0.000913	0.00576	CcSEcCtD
Nevirapine—Bone disorder—Methotrexate—ankylosing spondylitis	0.000885	0.00558	CcSEcCtD
Nevirapine—Ulcer—Methotrexate—ankylosing spondylitis	0.000845	0.00533	CcSEcCtD
Nevirapine—Hepatic enzyme increased—Methotrexate—ankylosing spondylitis	0.000845	0.00533	CcSEcCtD
Nevirapine—Dermatitis bullous—Betamethasone—ankylosing spondylitis	0.000834	0.00526	CcSEcCtD
Nevirapine—Dermatitis bullous—Dexamethasone—ankylosing spondylitis	0.000834	0.00526	CcSEcCtD
Nevirapine—Inflammation—Methotrexate—ankylosing spondylitis	0.000824	0.0052	CcSEcCtD
Nevirapine—Pancreatitis—Prednisolone—ankylosing spondylitis	0.00081	0.0051	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000773	0.00487	CcSEcCtD
Nevirapine—Skin exfoliation—Methotrexate—ankylosing spondylitis	0.000763	0.00481	CcSEcCtD
Nevirapine—Pancreatitis—Triamcinolone—ankylosing spondylitis	0.000744	0.00469	CcSEcCtD
Nevirapine—Pancreatitis—Methylprednisolone—ankylosing spondylitis	0.000743	0.00468	CcSEcCtD
Nevirapine—Mouth ulceration—Methotrexate—ankylosing spondylitis	0.000723	0.00456	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.000722	0.00455	CcSEcCtD
Nevirapine—Conjunctivitis—Prednisolone—ankylosing spondylitis	0.000716	0.00451	CcSEcCtD
Nevirapine—Lymphadenopathy—Methotrexate—ankylosing spondylitis	0.00068	0.00429	CcSEcCtD
Nevirapine—Face oedema—Prednisone—ankylosing spondylitis	0.00067	0.00423	CcSEcCtD
Nevirapine—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.000664	0.00418	CcSEcCtD
Nevirapine—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.000662	0.00418	CcSEcCtD
Nevirapine—Conjunctivitis—Triamcinolone—ankylosing spondylitis	0.000658	0.00415	CcSEcCtD
Nevirapine—Hepatic failure—Methotrexate—ankylosing spondylitis	0.000646	0.00407	CcSEcCtD
Nevirapine—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.000621	0.00392	CcSEcCtD
Nevirapine—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.000621	0.00392	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.000615	0.00388	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000612	0.00386	CcSEcCtD
Nevirapine—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.000602	0.0038	CcSEcCtD
Nevirapine—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.000602	0.0038	CcSEcCtD
Nevirapine—Conjunctivitis—Dexamethasone—ankylosing spondylitis	0.000597	0.00377	CcSEcCtD
Nevirapine—Conjunctivitis—Betamethasone—ankylosing spondylitis	0.000597	0.00377	CcSEcCtD
Nevirapine—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000596	0.00376	CcSEcCtD
Nevirapine—Pancreatitis—Prednisone—ankylosing spondylitis	0.000588	0.00371	CcSEcCtD
Nevirapine—Erythema—Prednisolone—ankylosing spondylitis	0.000575	0.00363	CcSEcCtD
Nevirapine—Neutropenia—Prednisone—ankylosing spondylitis	0.000561	0.00354	CcSEcCtD
Nevirapine—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.000548	0.00345	CcSEcCtD
Nevirapine—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000541	0.00341	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—ankylosing spondylitis	0.000536	0.00338	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.000534	0.00337	CcSEcCtD
Nevirapine—Erythema—Triamcinolone—ankylosing spondylitis	0.000529	0.00334	CcSEcCtD
Nevirapine—Erythema—Methylprednisolone—ankylosing spondylitis	0.000528	0.00333	CcSEcCtD
Nevirapine—Angioedema—Prednisolone—ankylosing spondylitis	0.000526	0.00331	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000524	0.00331	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.000522	0.00329	CcSEcCtD
Nevirapine—Malaise—Prednisolone—ankylosing spondylitis	0.000519	0.00327	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—ankylosing spondylitis	0.000496	0.00313	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000492	0.0031	CcSEcCtD
Nevirapine—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.000491	0.0031	CcSEcCtD
Nevirapine—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.00049	0.00309	CcSEcCtD
Nevirapine—Discomfort—Prednisolone—ankylosing spondylitis	0.000484	0.00305	CcSEcCtD
Nevirapine—Angioedema—Triamcinolone—ankylosing spondylitis	0.000483	0.00305	CcSEcCtD
Nevirapine—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000482	0.00304	CcSEcCtD
Nevirapine—Erythema—Dexamethasone—ankylosing spondylitis	0.00048	0.00303	CcSEcCtD
Nevirapine—Erythema—Betamethasone—ankylosing spondylitis	0.00048	0.00303	CcSEcCtD
Nevirapine—Malaise—Triamcinolone—ankylosing spondylitis	0.000477	0.00301	CcSEcCtD
Nevirapine—Malaise—Methylprednisolone—ankylosing spondylitis	0.000476	0.003	CcSEcCtD
Nevirapine—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000472	0.00298	CcSEcCtD
Nevirapine—Oedema—Prednisolone—ankylosing spondylitis	0.00047	0.00296	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00047	0.00296	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—ankylosing spondylitis	0.000469	0.00296	CcSEcCtD
Nevirapine—Myalgia—Triamcinolone—ankylosing spondylitis	0.00045	0.00284	CcSEcCtD
Nevirapine—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000449	0.00283	CcSEcCtD
Nevirapine—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000449	0.00283	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000446	0.00281	CcSEcCtD
Nevirapine—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000445	0.00281	CcSEcCtD
Nevirapine—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000445	0.00281	CcSEcCtD
Nevirapine—Discomfort—Triamcinolone—ankylosing spondylitis	0.000445	0.00281	CcSEcCtD
Nevirapine—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000444	0.0028	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000443	0.00279	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—ankylosing spondylitis	0.00044	0.00277	CcSEcCtD
Nevirapine—Angioedema—Dexamethasone—ankylosing spondylitis	0.000439	0.00277	CcSEcCtD
Nevirapine—Angioedema—Betamethasone—ankylosing spondylitis	0.000439	0.00277	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000435	0.00274	CcSEcCtD
Nevirapine—Immune system disorder—Prednisone—ankylosing spondylitis	0.000434	0.00274	CcSEcCtD
Nevirapine—Malaise—Betamethasone—ankylosing spondylitis	0.000433	0.00273	CcSEcCtD
Nevirapine—Malaise—Dexamethasone—ankylosing spondylitis	0.000433	0.00273	CcSEcCtD
Nevirapine—Oedema—Triamcinolone—ankylosing spondylitis	0.000432	0.00272	CcSEcCtD
Nevirapine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000432	0.00272	CcSEcCtD
Nevirapine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000431	0.00272	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000423	0.00267	CcSEcCtD
Nevirapine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000423	0.00266	CcSEcCtD
Nevirapine—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000422	0.00266	CcSEcCtD
Nevirapine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000418	0.00264	CcSEcCtD
Nevirapine—Erythema—Prednisone—ankylosing spondylitis	0.000418	0.00264	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000417	0.00263	CcSEcCtD
Nevirapine—Myalgia—Dexamethasone—ankylosing spondylitis	0.000409	0.00258	CcSEcCtD
Nevirapine—Myalgia—Betamethasone—ankylosing spondylitis	0.000409	0.00258	CcSEcCtD
Nevirapine—Discomfort—Dexamethasone—ankylosing spondylitis	0.000404	0.00255	CcSEcCtD
Nevirapine—Discomfort—Betamethasone—ankylosing spondylitis	0.000404	0.00255	CcSEcCtD
Nevirapine—Pain—Prednisolone—ankylosing spondylitis	0.000402	0.00253	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—ankylosing spondylitis	0.000401	0.00253	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000393	0.00248	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000393	0.00248	CcSEcCtD
Nevirapine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000392	0.00247	CcSEcCtD
Nevirapine—Oedema—Betamethasone—ankylosing spondylitis	0.000392	0.00247	CcSEcCtD
Nevirapine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000392	0.00247	CcSEcCtD
Nevirapine—Oedema—Dexamethasone—ankylosing spondylitis	0.000392	0.00247	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000388	0.00245	CcSEcCtD
Nevirapine—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000388	0.00244	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000387	0.00244	CcSEcCtD
Nevirapine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000387	0.00244	CcSEcCtD
Nevirapine—Anaemia—Prednisone—ankylosing spondylitis	0.000386	0.00244	CcSEcCtD
Nevirapine—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000384	0.00242	CcSEcCtD
Nevirapine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000384	0.00242	CcSEcCtD
Nevirapine—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000384	0.00242	CcSEcCtD
Nevirapine—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000384	0.00242	CcSEcCtD
Nevirapine—Angioedema—Prednisone—ankylosing spondylitis	0.000382	0.00241	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000379	0.00239	CcSEcCtD
Nevirapine—Malaise—Prednisone—ankylosing spondylitis	0.000377	0.00238	CcSEcCtD
Nevirapine—Anorexia—Betamethasone—ankylosing spondylitis	0.000373	0.00235	CcSEcCtD
Nevirapine—Anorexia—Dexamethasone—ankylosing spondylitis	0.000373	0.00235	CcSEcCtD
Nevirapine—Urticaria—Prednisolone—ankylosing spondylitis	0.000373	0.00235	CcSEcCtD
Nevirapine—Fatigue—Triamcinolone—ankylosing spondylitis	0.000372	0.00235	CcSEcCtD
Nevirapine—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000371	0.00234	CcSEcCtD
Nevirapine—Pain—Triamcinolone—ankylosing spondylitis	0.000369	0.00233	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000363	0.00229	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000357	0.00225	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000357	0.00225	CcSEcCtD
Nevirapine—Myalgia—Prednisone—ankylosing spondylitis	0.000356	0.00224	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—ankylosing spondylitis	0.000356	0.00224	CcSEcCtD
Nevirapine—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000356	0.00224	CcSEcCtD
Nevirapine—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000355	0.00224	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000353	0.00223	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000352	0.00222	CcSEcCtD
Nevirapine—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000352	0.00222	CcSEcCtD
Nevirapine—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000352	0.00222	CcSEcCtD
Nevirapine—Discomfort—Prednisone—ankylosing spondylitis	0.000352	0.00222	CcSEcCtD
Nevirapine—Erythema—Methotrexate—ankylosing spondylitis	0.000349	0.0022	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000346	0.00218	CcSEcCtD
Nevirapine—Urticaria—Triamcinolone—ankylosing spondylitis	0.000343	0.00216	CcSEcCtD
Nevirapine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000342	0.00216	CcSEcCtD
Nevirapine—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000341	0.00215	CcSEcCtD
Nevirapine—Oedema—Prednisone—ankylosing spondylitis	0.000341	0.00215	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000341	0.00215	CcSEcCtD
Nevirapine—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000341	0.00215	CcSEcCtD
Nevirapine—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000341	0.00215	CcSEcCtD
Nevirapine—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000341	0.00215	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000338	0.00213	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000338	0.00213	CcSEcCtD
Nevirapine—Fatigue—Betamethasone—ankylosing spondylitis	0.000338	0.00213	CcSEcCtD
Nevirapine—Fatigue—Dexamethasone—ankylosing spondylitis	0.000338	0.00213	CcSEcCtD
Nevirapine—Pain—Dexamethasone—ankylosing spondylitis	0.000335	0.00211	CcSEcCtD
Nevirapine—Pain—Betamethasone—ankylosing spondylitis	0.000335	0.00211	CcSEcCtD
Nevirapine—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000335	0.00211	CcSEcCtD
Nevirapine—Skin disorder—Prednisone—ankylosing spondylitis	0.000331	0.00209	CcSEcCtD
Nevirapine—Anorexia—Prednisone—ankylosing spondylitis	0.000325	0.00205	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000324	0.00204	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—ankylosing spondylitis	0.000323	0.00204	CcSEcCtD
Nevirapine—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000323	0.00204	CcSEcCtD
Nevirapine—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000323	0.00204	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00032	0.00202	CcSEcCtD
Nevirapine—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00032	0.00202	CcSEcCtD
Nevirapine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000318	0.00201	CcSEcCtD
Nevirapine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000317	0.002	CcSEcCtD
Nevirapine—Malaise—Methotrexate—ankylosing spondylitis	0.000315	0.00199	CcSEcCtD
Nevirapine—Urticaria—Dexamethasone—ankylosing spondylitis	0.000311	0.00196	CcSEcCtD
Nevirapine—Urticaria—Betamethasone—ankylosing spondylitis	0.000311	0.00196	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000311	0.00196	CcSEcCtD
Nevirapine—Asthenia—Triamcinolone—ankylosing spondylitis	0.00031	0.00195	CcSEcCtD
Nevirapine—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00031	0.00195	CcSEcCtD
Nevirapine—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00031	0.00195	CcSEcCtD
Nevirapine—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00031	0.00195	CcSEcCtD
Nevirapine—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00031	0.00195	CcSEcCtD
Nevirapine—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000309	0.00195	CcSEcCtD
Nevirapine—Paraesthesia—Prednisone—ankylosing spondylitis	0.000306	0.00193	CcSEcCtD
Nevirapine—Pruritus—Triamcinolone—ankylosing spondylitis	0.000305	0.00193	CcSEcCtD
Nevirapine—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000305	0.00192	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—ankylosing spondylitis	0.000297	0.00188	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—ankylosing spondylitis	0.000297	0.00188	CcSEcCtD
Nevirapine—Decreased appetite—Prednisone—ankylosing spondylitis	0.000297	0.00187	CcSEcCtD
Nevirapine—Rash—Prednisolone—ankylosing spondylitis	0.000296	0.00187	CcSEcCtD
Nevirapine—Dermatitis—Prednisolone—ankylosing spondylitis	0.000296	0.00187	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000295	0.00186	CcSEcCtD
Nevirapine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000295	0.00186	CcSEcCtD
Nevirapine—Fatigue—Prednisone—ankylosing spondylitis	0.000294	0.00185	CcSEcCtD
Nevirapine—Headache—Prednisolone—ankylosing spondylitis	0.000294	0.00185	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—ankylosing spondylitis	0.000294	0.00185	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000285	0.0018	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000281	0.00177	CcSEcCtD
Nevirapine—Asthenia—Dexamethasone—ankylosing spondylitis	0.000281	0.00177	CcSEcCtD
Nevirapine—Asthenia—Betamethasone—ankylosing spondylitis	0.000281	0.00177	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00028	0.00176	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000279	0.00176	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000279	0.00176	CcSEcCtD
Nevirapine—Nausea—Prednisolone—ankylosing spondylitis	0.000279	0.00176	CcSEcCtD
Nevirapine—Pruritus—Dexamethasone—ankylosing spondylitis	0.000277	0.00175	CcSEcCtD
Nevirapine—Pruritus—Betamethasone—ankylosing spondylitis	0.000277	0.00175	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—ankylosing spondylitis	0.000277	0.00175	CcSEcCtD
Nevirapine—Vomiting—Triamcinolone—ankylosing spondylitis	0.000275	0.00173	CcSEcCtD
Nevirapine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000274	0.00173	CcSEcCtD
Nevirapine—Rash—Triamcinolone—ankylosing spondylitis	0.000272	0.00172	CcSEcCtD
Nevirapine—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000272	0.00172	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—ankylosing spondylitis	0.000272	0.00171	CcSEcCtD
Nevirapine—Rash—Methylprednisolone—ankylosing spondylitis	0.000272	0.00171	CcSEcCtD
Nevirapine—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000271	0.00171	CcSEcCtD
Nevirapine—Urticaria—Prednisone—ankylosing spondylitis	0.000271	0.00171	CcSEcCtD
Nevirapine—Headache—Triamcinolone—ankylosing spondylitis	0.000271	0.00171	CcSEcCtD
Nevirapine—Headache—Methylprednisolone—ankylosing spondylitis	0.00027	0.0017	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—ankylosing spondylitis	0.00027	0.0017	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—ankylosing spondylitis	0.00027	0.0017	CcSEcCtD
Nevirapine—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000268	0.00169	CcSEcCtD
Nevirapine—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000268	0.00169	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.00026	0.00164	CcSEcCtD
Nevirapine—Nausea—Triamcinolone—ankylosing spondylitis	0.000256	0.00162	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000256	0.00161	CcSEcCtD
Nevirapine—Nausea—Methylprednisolone—ankylosing spondylitis	0.000256	0.00161	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—ankylosing spondylitis	0.000254	0.0016	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000251	0.00159	CcSEcCtD
Nevirapine—Vomiting—Dexamethasone—ankylosing spondylitis	0.000249	0.00157	CcSEcCtD
Nevirapine—Vomiting—Betamethasone—ankylosing spondylitis	0.000249	0.00157	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000248	0.00156	CcSEcCtD
Nevirapine—Rash—Dexamethasone—ankylosing spondylitis	0.000247	0.00156	CcSEcCtD
Nevirapine—Rash—Betamethasone—ankylosing spondylitis	0.000247	0.00156	CcSEcCtD
Nevirapine—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000247	0.00156	CcSEcCtD
Nevirapine—Dermatitis—Betamethasone—ankylosing spondylitis	0.000247	0.00156	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000246	0.00155	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—ankylosing spondylitis	0.000246	0.00155	CcSEcCtD
Nevirapine—Headache—Betamethasone—ankylosing spondylitis	0.000245	0.00155	CcSEcCtD
Nevirapine—Headache—Dexamethasone—ankylosing spondylitis	0.000245	0.00155	CcSEcCtD
Nevirapine—Asthenia—Prednisone—ankylosing spondylitis	0.000245	0.00154	CcSEcCtD
Nevirapine—Pain—Methotrexate—ankylosing spondylitis	0.000244	0.00154	CcSEcCtD
Nevirapine—Pruritus—Prednisone—ankylosing spondylitis	0.000241	0.00152	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000235	0.00148	CcSEcCtD
Nevirapine—Diarrhoea—Prednisone—ankylosing spondylitis	0.000233	0.00147	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000233	0.00147	CcSEcCtD
Nevirapine—Nausea—Dexamethasone—ankylosing spondylitis	0.000233	0.00147	CcSEcCtD
Nevirapine—Nausea—Betamethasone—ankylosing spondylitis	0.000233	0.00147	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—ankylosing spondylitis	0.000227	0.00143	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000225	0.00142	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000225	0.00142	CcSEcCtD
Nevirapine—Vomiting—Prednisone—ankylosing spondylitis	0.000217	0.00137	CcSEcCtD
Nevirapine—Rash—Prednisone—ankylosing spondylitis	0.000215	0.00136	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—ankylosing spondylitis	0.000215	0.00136	CcSEcCtD
Nevirapine—Headache—Prednisone—ankylosing spondylitis	0.000214	0.00135	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00021	0.00132	CcSEcCtD
Nevirapine—Asthenia—Methotrexate—ankylosing spondylitis	0.000205	0.00129	CcSEcCtD
Nevirapine—Nausea—Prednisone—ankylosing spondylitis	0.000203	0.00128	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—ankylosing spondylitis	0.000202	0.00127	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000195	0.00123	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—ankylosing spondylitis	0.000181	0.00114	CcSEcCtD
Nevirapine—Rash—Methotrexate—ankylosing spondylitis	0.00018	0.00113	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—ankylosing spondylitis	0.00018	0.00113	CcSEcCtD
Nevirapine—Headache—Methotrexate—ankylosing spondylitis	0.000179	0.00113	CcSEcCtD
Nevirapine—Nausea—Methotrexate—ankylosing spondylitis	0.000169	0.00107	CcSEcCtD
